Prothena Corporation plc revised earnings guidance for the year 2021. For the year, the company estimates net income to be in the range of $50 million to $60 million versus prior net loss guidance of $79 million to $111 million, which includes the payments from Bristol Myers Squibb and Novo Nordisk mentioned above, as well as an estimated $25 million of non-cash share-based compensation expense.